Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.
Research context
Hisamitsu Pharmaceutical Co., Inc appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Hisamitsu Pharmaceutical Co., Inc is currently in a long term downtrend where the price is trading 15.4% below its 200 day moving average.
From a valuation standpoint, the stock is 93.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.9.
Hisamitsu Pharmaceutical Co., Inc's total revenue sank by 21.8% to $28B since the same quarter in the previous year.
Its net income has dropped by 74.2% to $2B since the same quarter in the previous year.
Based on the above factors, Hisamitsu Pharmaceutical Co., Inc gets an overall score of 1/5.